Oncopeptides

European Pricing And Regulatory Pressures Will Erode Value

AnalystLowTarget

Not Invested

Community Contributor

Published

18 Aug 25

AnalystLowTarget's Fair Value

SEK 1.70

204.1% overvalued

18 Aug

SEK 5.17

146.8%

-7.8%

146.8%

-7.8%

You can edit this narrative until Aug 18 10:12 PM. Then, changes will post as Updates.

Author's Valuation

SEK 1.7204.1% overvalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

SEK 1.7

204.1% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

66.20%

Biotech revenue growth rate

9.05%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

4.92%

Calculation

SEK 87.00m

Earnings '28

5.87x

PE Ratio '28

SEK 510.47m

Market Cap '28

SEK 510.47m

Market Cap '28

260.70m

No. shares '28

SEK 1.96

Share Price '28

SEK 1.96 Share Price '28

Discounted to 2025 @ 4.92% p.a.

SEK 1.70

Fair Value '25